Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

← catalyst calendar

NCT04036682

Sponsored by Cullinan Therapeutics Inc. (industry) · CGEM — their whole pipeline →. With Taiho Oncology, Inc..

Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
284estimated
Sites
64
Countries
Hong Kong, Italy, Japan +6

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2019-10-31actualWhen the study began enrolling
Primary completion2025-10-13actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2028-03-31estimatedThe whole study's end, after follow-up
First posted2019-07-30actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-06-17actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Non Small Cell Lung Cancer
  • EGFR Exon 20 Mutation

Intervention

  • Drug: CLN-081 — also filed as TAS6417; zipalertinib

Primary outcomes

what the primary-completion date above is the date OF
All Cohorts: The rate and severity of treatment emergent AEs.
measured 24 months
All Cohorts: The rate and severity of DLTs.
measured 24 months
Phase 2 Dose Expansion Cohorts: Overall response rate (ORR)
measured 24 months
Module A: Pharmacokinetic (PK) parameter
measured 24 months
Module A: Pharmacokinetic (PK) parameter
measured 24 months
Module B and C: Confirmed overall response rate (ORR) and duration of response (DOR) by independent review committee (IRC)
measured 24 months

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · CGEM's whole pipeline · Catalyst calendar · Every registered study · What changed